Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Non-interventional Observational Study on the Influence of Pramipexole on Sensory Symptoms of Restless Legs Syndrome (RLS)

Completed

Conditions: Restless Legs Syndrome

First Posted Date: 2009-04-23

Last Posted Date: 2014-06-27

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1504

Registration Number: NCT00887289

Locations: 🇩🇪
Boehringer Ingelheim Investigational Site 1, Zwickau, Germany
🇩🇪
Boehringer Ingelheim Investigational Site 2, Zwickau, Germany
🇩🇪
Boehringer Ingelheim Investigational Site 3, Wuppertal, Germany

and more 31 locations

TELMA - Observational Study in Daily Medical Practice of the Effectiveness of Telmisartan for Treatment of Hypertension in Patients With and Without Confirmed Albuminuria in Belgium

Completed

Conditions: Hypertension

First Posted Date: 2009-04-22

Last Posted Date: 2014-06-17

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 2874

Registration Number: NCT00886288

Locations: 🇧🇪
Boehringer Ingelheim Investigational Site 17, Alleur, Belgium
🇧🇪
Boehringer Ingelheim Investigational Site 22, Amougies, Belgium
🇧🇪
Boehringer Ingelheim Investigational Site 23, Anderlues, Belgium

and more 933 locations

MEN STUDY (ESTUDIO MEN) Quality of Life in Patients With BPH and Nocturia Before and After Tamsulosin Ocas® Treatment

Completed

Conditions: Prostatic Hyperplasia

First Posted Date: 2009-04-21

Last Posted Date: 2013-11-14

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1342

Registration Number: NCT00885027

Locations: 🇨🇴
Boehringer Ingelheim Investigational Site, Villavicencio, Colombia

4 Weeks Treatment With Empagliflozin (BI 10773) in Japanese Type 2 Diabetic Patients (T2DM)

Phase 2

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Placebo (middle dose)
Drug: BI 10773
Drug: Placebo
Drug: Placebo (high dose)
Drug: Placebo (low dose)

First Posted Date: 2009-04-21

Last Posted Date: 2014-11-25

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 100

Registration Number: NCT00885118

Locations: 🇯🇵
1245.15.003 Boehringer Ingelheim Investigational Site, Hachioji, Tokyo, Japan
🇯🇵
1245.15.002 Boehringer Ingelheim Investigational Site, Koganei, Tokyo, Japan
🇯🇵
1245.15.005 Boehringer Ingelheim Investigational Site, Suita, Osaka, Japan

and more 2 locations

Empagliflozin (BI 10773) in Type Two Diabetes (T2D) Patients, Open Label Extension

Phase 2

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: BI 10773
Drug: Metformin
Drug: Sitagliptin

First Posted Date: 2009-04-15

Last Posted Date: 2014-06-16

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 660

Registration Number: NCT00881530

Locations: 🇺🇸
1245.24.101006 Boehringer Ingelheim Investigational Site, Wadsworth, Ohio, United States
🇺🇸
1245.24.101024 Boehringer Ingelheim Investigational Site, St. Cloud, Florida, United States
🇺🇸
1245.24.101015 Boehringer Ingelheim Investigational Site, Dallas, Texas, United States

and more 134 locations

Investigating the Effect of Telmisartan (Micardis®) on the Average 24h Blood Pressure of Therapy-naive and Therapy-experienced Patients

Completed

Conditions: Hypertension

Interventions: Drug: Micardis

First Posted Date: 2009-04-10

Last Posted Date: 2014-03-28

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 670

Registration Number: NCT00879411

Telmisartan Fixed Dose Combination vs Amlodipine in Hypertensive Patients With Type 2 Diabetes Mellitus

Phase 3

Completed

Conditions: Hypertension

Interventions: Drug: Telmisartan 80
Drug: Amlodipine 10

First Posted Date: 2009-04-08

Last Posted Date: 2014-03-12

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 706

Registration Number: NCT00877929

Locations: 🇺🇸
1235.21.907 Boehringer Ingelheim Investigational Site, Tustin, California, United States
🇺🇸
1235.21.913 Boehringer Ingelheim Investigational Site, Fort Lauderdale, Florida, United States
🇺🇸
1235.21.910 Boehringer Ingelheim Investigational Site, Hollywood, Florida, United States

and more 62 locations

Non-Interventional Observational Study With Viramune Plus Antiretroviral in HIV Infected Patients

Completed

Conditions: HIV Infections

First Posted Date: 2009-04-07

Last Posted Date: 2015-01-16

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 605

Registration Number: NCT00876733

Locations: 🇩🇪
Boehringer Ingelheim Investigational Site 15, Berlin, Germany
🇩🇪
Boehringer Ingelheim Investigational Site 12, Berlin, Germany
🇩🇪
Boehringer Ingelheim Investigational Site 14, Aachen, Germany

and more 63 locations

BIBF 1120 + Docetaxel (Japan) in Patients With Advanced Non-small-cell Lung Cancer, Phase I

Phase 1

Completed

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: BIBF 1120 M + docetaxel M
Drug: BIBF 1120 M + docetaxel H
Drug: BIBF 1120 H + docetaxel H
Drug: BIBF 1120 L + docetaxel M
Drug: BIBF 1120 H + docetaxel M

First Posted Date: 2009-04-06

Last Posted Date: 2016-11-17

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 43

Registration Number: NCT00876460

Locations: 🇯🇵
1199.29.002 Boehringer Ingelheim Investigational Site, Fukuoka, Fukuoka, Japan
🇯🇵
1199.29.001 Boehringer Ingelheim Investigational Site, Osaka-Sayamashi, Osaka, Japan

Afatinib (BIBW 2992) QTcF Trial in Patients With Relapsed or Refractory Solid Tumours

Phase 2

Completed

Conditions: Neoplasms

Interventions: Drug: BIBW 2992

First Posted Date: 2009-04-03

Last Posted Date: 2013-12-30

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 60

Registration Number: NCT00875433

Locations: 🇬🇧
1200.24.4401 Boehringer Ingelheim Investigational Site, Sutton, United Kingdom
🇬🇧
1200.24.4402 Boehringer Ingelheim Investigational Site, London, United Kingdom
🇬🇧
1200.24.4403 Boehringer Ingelheim Investigational Site, Guildford, United Kingdom

and more 1 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy